instruction:
Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
question:
The story does not mention the costs of screening or follow-up tests or treatment to the individual or, collectively, to society. Those costs are significant. This story uses several different statistics and expert perspectives to explain what the researchers found in their examination of the effects of mammography screening. It not only include the relative risk reduction (10 percent) and an absolute risk reduction statistic (among women in their 50s, a decade of screening would boost the likelihood of avoiding a fatal breast cancer from 995.6 out of 1,000 to 996 out of 1,000), but it also offered comments from different experts about how they would personally value effects of that size. The story notes that screening mammography exposes women to false alarms scares as well as the risks and harms of treating tumors that actually would not have become life-threatening. This story explains how this study is different from earlier research on mammography. It points out both advantages of the study methods (comparing women in regions with screening to those without as Norway rolled out a national program over a 9 year period) and limitations (an observational study like this is not as powerful as a randomized trial, and the study might have found more benefits to screening if it had lasted longer). The story also noted the uncertainty in the numbers the researchers reported and that the real differences might be different. The story does not exaggerate the risk of breast cancer or the need to be screened for it. The story includes comments from several independent sources offering a variety of perspectives. It does not mention that the study was funded by the Cancer Registry of Norway and the Research Council of Norway. The story notes that improved treatments appear to have reduced the breast cancer death rate even among women who did not have regular screening mammograms. Not being screened was clearly acknowledged as an alternative, something not all competing stories explicitly addressed. The availability of mammography screening is not at issue. This story does point out that the women who were screened in Norway had access to special treatment teams. And it noted that these treatments are available at "many major medical centers in the United States." Mammography is not new, but this story does a good job of explaining what is new about the way these researchers examined the effects of screening. The story includes comments from several sources and does not appear to rely on a news release.
answer:
Mammograms' Value in Cancer Fight at Issue

question:
While governments in at least 20 other states obtained more than 30 million doses of the drug through donations from the federal reserve or private companies, Oklahoma and Utah instead bought them from private pharmaceutical companies. Top officials in both states chalked up the decisions to "the fog of war." Oklahoma Gov. Kevin Stitt on Tuesday defended the state's $2 million purchase, saying the drug was showing some promise. His health secretary attributed buying the 1.2 million hydroxychloroquine pills to something that happens in the "fog of war." Utah Gov. Gary Herbert at first defended the state's $800,000 purchase of 20,000 packets of hydroxychloroquine compounded with zinc, but has since ordered an investigation of a no-bid contract with a local company that had been promoting the drugs. Herbert, a Republican, also canceled an additional plan to spend $8 million more to buy 200,000 additional treatments from the same company. A left-leaning nonprofit group in Utah filed a price gouging complaint Tuesday with state regulators, arguing the $40 per pack drug was grossly overpriced. Oklahoma's attorney general requested an investigative audit on Tuesday of its Department of Health over spending and warned the agency about retaliating against employees who report wrongful government activities under the state's Whistleblower Act. A spokesman for Attorney General Mike Hunter declined to comment on whether the request was related to the $2 million spent on the drug. Doctors can already prescribe the malaria drug to patients with COVID-19, a practice known as off-label prescribing, and many do. But the U.S. Food and Drug Administration on Friday warned doctors against prescribing hydroxychloroquine for treating the coronavirus outside of hospitals or research settings because of reports of serious side effects, including irregular heart rhythms and death among patients. Preliminary results from a recent study done on coronavirus patients at U.S. veterans hospitals showed no benefit, casting more doubt on the drug's efficacy during the pandemic. Those were the latest admonitions against the drug that Trump has regularly promoted in public appearances, touting its potential despite his own health advisors telling him it is unproven. Oklahoma acquired 1.2 million pills, or about 100,000 doses, on April 4 from FFF Enterprises, a California-based medical supply wholesaler, according to the Oklahoma State Department of Health. Oklahoma state Rep. Melissa Provenzano, a Democrat from Tulsa, said the state's purchase shows that Gov. Stitt's actions don't follow his claim that he relies on data to drive his decisions. "Two million dollars is a lot of money to waste, especially when we have unemployment claims approved yet going unpaid, health care professionals without proper protective equipment, and diagnosed cases and deaths continuing to rise," Provenzano said. Stitt, a first-term Republican, said hydroxychloroquine was showing some promise as a treatment in early March, and he didn't want Oklahoma to miss out on an opportunity to acquire it. "Now there's some evidence the chloroquine may not be as effective, but I was being proactive to try and protect Oklahomans," Stitt said Tuesday when asked about the purchase. "That's always going to be my first instinct, to get the equipment and things we need that I'm seeing in the future would help Oklahomans." Oklahoma's Secretary of Health Jerome Loughridge said several physicians, including some in Oklahoma, were previously optimistic about the drug's promise in treating COVID-19. He added that the drug is also useful for treating lupus and some other auto-immune diseases, so the state's supply "will not have gone to waste." "When we were battling sort of the fog of war at that point, we certainly acquired it on the potential that it would have utility," Loughridge said. Jeff Burton, a former adjutant general of the Utah National Guard chosen to lead the state health department's coronavirus task force, offered a similar explanation for why the state made its purchase. He said the state never received the pills and is trying to get its money back. "I chalk it up to fog of war," Burton told the state's pharmacy board. "There was a lot going on. It's easy to judge it from (an) easy chair.. . . Since then we've decided that was not a wise purchase." Doctors in Oklahoma have been using the drug to treat patients with COVID-19, often in conjunction with a second drug, azithromiocin, but the results "just are not that promising," said Dr. Douglas Drevets, chief of infectious diseases at University of Oklahoma Medicine. FFF Enterprises said it's the company's policy not to comment on transactions with customers. Utah gave a local company called Meds in Motion the $800,000 contract without taking bids from other companies under emergency procurement rules, said Christopher Hughes, director of Utah's division of purchasing. State officials haven't explained why they didn't seek to get the drugs for free. The Federal Emergency Management Agency said Saturday it has sent out 28.6 million tablets of hydroxychloroquine sulfate free of cost to states around the country. Several states including New York, Connecticut and Texas received donations of the medication from a private company based in New Jersey called Amneal Pharmaceutical, according to information compiled by The Associated Press. Utah taxpayers deserve to know what happened to allow a purchase that seems like a company taking advantage of the early, chaotic days of the pandemic, said Chase Thomas, executive director of the group called Alliance for a Better Utah that submitted the price gouging complaint. The complaint alleges Utah paid at least double the common price for the medication. "Whether they were buying drugs we didn't need or paying too much for it when they could have gotten them for free, there just needed to be a lot more thought going into this," Thomas said. Meds in Motion didn't answer an email seeking comment about the allegations. Herbert declined to provide an update Tuesday about the investigation of the purchase. He said Friday the state's legal counsel would aim to find out what, how and why it happened. He said he believed state officials acted in good faith as they scrambled to slow the spread of coronavirus, but acknowledged a mistake may have been made. "I have some questions about how it came about," Herbert said Friday. "Bottom line is, we're not purchasing any more of this drug." ___ McCombs and Whitehurst reported from Salt Lake City.
answer:
Oklahoma, Utah face scrutiny over malaria drug purchases.

question:
North Kivu Governor Carly Kasivita, who organized the march, said that anyone spreading misinformation and claiming that "Ebola is a business" will face arrest. "We are very concerned ... Some pastors, some politicians, are venturing into the public health debate and disorienting many of our citizens with misinformation. These pastors who deny the existence of Ebola will be put in jail as soon as they are caught," Kasivita said. The governor also promised more marches and initiatives to raise awareness in other parts of the province, including Beni and Butembo where Ebola also has spread. "The message is to say we must stop this disease in the province. In the same way that we are concerned about security in the province, we are also concerned about Ebola," he said. People rode bikes alongside police, soldiers and residents in Goma carrying banners and wearing T-shirts that said STOP. "We do not want other countries to be contaminated through our beautiful province of North Kivu. We want everyone to contribute to Ebola's end," Kasivita said. "People need to understand that the disease exists and we call on rebel groups to work with response teams because there are environments where teams cannot get because of insecurity." The Ebola outbreak, which has killed more than 1,800 people since it was declared one year ago in eastern Congo, has not shown signs of slowing down despite new treatments and vaccines given to more than 197,000 people in the region. New cases emerged in Goma, the capital of North Kivu, in recent months and have spread to a new province in the past week. Insecurity has been one factor in a region where rebel groups have fought for control of mineral-rich lands for decades. Ebola also has spread because of mistrust by communities who have also staged attacks against health workers. The governor of South Kivu and his Rwandan counterpart in the Western Province signed a bilateral agreement on Wednesday in Bukavu to unite their efforts in the fight against Ebola, while respecting peoples' rights to cross borders. To help combat further spread of Ebola, however, the two delegations agreed to exchange specific information, including a list of high-risk people, said Daniel Lwaboshi, deputy chief of staff of the governor of South Kivu. "These are those people who have been in contact with the sick, because we have them in our province," he said. Measures are already in place. Days ago, several people from South Kivu had been prevented from crossing the border.
answer:
Hundreds gather in Goma, Congo for "Stop Ebola" march.